Literature DB >> 9736566

In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

D Andes1, W A Craig.   

Abstract

The in vivo activities of amoxicillin and amoxicillin-clavulanate against 17 strains of Streptococcus pneumoniae with penicillin MICs of 0.12-8.0 mg/liter were assessed in a cyclophosphamide-induced neutropenic murine thigh infection model. Renal impairment was produced by administration of uranyl nitrate to prolong the amoxicillin half-life in the mice from 21 to 65 min, simulating human pharmacokinetics. Two hours after thigh infection with 10(5) to 10(6) CFU, groups of mice were treated with 7 mg of amoxicillin per kg of body weight alone or combined with clavulanate (ratio, 4:1) every 8 h for 1 and 4 days. There was an excellent correlation between the MIC of amoxicillin (0.03 to 5.6 mg/liter) and (i) the change in log10 CFU/thigh at 24 h and (ii) survival after 4 days of therapy. Organisms for which MICs were 2 mg/liter or less were killed at 1.4 to 4.2 and 1.6 to 4.1 log10 CFU/thigh at 24 h by amoxicillin and amoxicillin-clavulanate, respectively. The four strains for which MICs were >4 mg/liter grew 0.2 to 2.6 and 0.6 to 2. 3 logs at 24 h despite therapy with amoxicillin and amoxicillin-clavulanate, respectively. Infection was uniformly fatal by 72 h in untreated mice. Amoxicillin therapy resulted in no mortality with organisms for which MICs were 1 mg/liter or less, 20 to 40% mortality with organisms for which MICs were 2 mg/liter, and 80 to 100% mortality with organisms for which MICs were 4.0-5.6 mg/liter. Lower and higher doses (0.5, 2, and 20 mg/kg) of amoxicillin were studied against organisms for which MICs were near the breakpoint. These studies demonstrate that a reduction of 1 log10 or greater in CFU/thigh at 24 h is consistently observed when amoxicillin levels exceed the MIC for 25 to 30% of the dosing interval. These studies would support amoxicillin (and amoxicillin-clavulanate) MIC breakpoints of 1 mg/liter for susceptible, 2 mg/liter for intermediate, and 4 mg/liter for resistant strains of S. pneumoniae.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736566      PMCID: PMC105836     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  National gonorrhea therapy monitoring study: in vitro antibiotic susceptibility and its correlation with treatment results.

Authors:  H W Jaffe; J W Biddle; C Thornsberry; R E Johnson; R E Kaufman; G H Reynolds; P J Wiesner
Journal:  N Engl J Med       Date:  1976-01-01       Impact factor: 91.245

2.  Correlation between in vitro studies and response to antibiotic therapy in staphylococcic bacteremia.

Authors:  F M ABBOUD; B A WAISBREN
Journal:  AMA Arch Intern Med       Date:  1959-08

3.  Imipenem-cilastatin therapy in a child with meningitis caused by a multiply resistant pneumococcus.

Authors:  F Asensi; D Pérez-Tamarit; M C Otero; M Gallego; S Llanes; C Abadia; E Cantó
Journal:  Pediatr Infect Dis J       Date:  1989-12       Impact factor: 2.129

4.  Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model.

Authors:  B Vogelman; S Gudmundsson; J Leggett; J Turnidge; S Ebert; W A Craig
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

Review 6.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

7.  Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins.

Authors:  N Frimodt-Møller; M W Bentzon; V F Thomsen
Journal:  J Infect Dis       Date:  1986-09       Impact factor: 5.226

8.  Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis.

Authors:  I R Friedland; S Shelton; M Paris; S Rinderknecht; S Ehrett; K Krisher; G H McCracken
Journal:  Pediatr Infect Dis J       Date:  1993-03       Impact factor: 2.129

9.  Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Authors:  J E Leggett; B Fantin; S Ebert; K Totsuka; B Vogelman; W Calame; H Mattie; W A Craig
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

10.  Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections.

Authors:  W A Craig; J Redington; S C Ebert
Journal:  J Antimicrob Chemother       Date:  1991-05       Impact factor: 5.790

View more
  103 in total

1.  Influence of Pharmacokinetic and Pharmacodynamic Principles on Antibiotic Selection.

Authors:  George G. Zhanel
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.

Authors:  Kiyoshi Sugihara; Chika Sugihara; Yoko Matsushita; Naotoshi Yamamura; Mitsutoshi Uemori; Akane Tokumitsu; Harumi Inoue; Masayo Kakuta; Eiko Namba; Hatsumi Nasu; Tetsufumi Koga
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.

Authors:  Dora E Wiskirchen; Jared L Crandon; Guilherme H Furtado; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

4.  Simulation of human gentamicin pharmacokinetics in an experimental Enterococcus faecalis endocarditis model.

Authors:  Laurent Dubé; Jocelyne Caillon; Christèle Gras-Le Guen; Cédric Jacqueline; Marie-France Kergueris; Jean-Claude Granry; Gilles Potel; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 5.  In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis.

Authors:  David Andes
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

6.  In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; J Lowther; A Bryskier; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

7.  Eradication of Streptococcus pneumoniae in the Nasopharyngeal Flora of Children with Acute Otitis Media after Amoxicillin/Clavulanate Therapy.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

8.  Microbial growth inhibition by alternating electric fields in mice with Pseudomonas aeruginosa lung infection.

Authors:  Moshe Giladi; Yaara Porat; Alexandra Blatt; Esther Shmueli; Yoram Wasserman; Eilon D Kirson; Yoram Palti
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

9.  Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model.

Authors:  Myo-Kyoung Kim; Wen Zhou; Pamela R Tessier; Dawei Xuan; Min Ye; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

10.  In vivo efficacy of humanized ceftaroline fosamil-avibactam exposures in a polymicrobial infection model.

Authors:  Amira A Bhalodi; Jared L Crandon; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.